Kitov Pharmaceuticals Holdings Ltd (NASDAQ: KTOV) was founded on August 12, 1968, headquartered in Tel Aviv, Israel, with 2 full-time employees (9/24/2015). It is a biopharmaceutical company dedicated to pain and pain caused by osteoarthritis. Treatment of hypertension.
Kitov Pharmaceuticals (KTOV):
Kitov is a biopharmaceutical company focusing on the late-stage development of existing drugs (generic drugs), currently focusing on two aspects: arthritis & hypertension. There are currently two Kitov product lines, KIT- 301 and KIT- 302.
- KIT-301: Based on the generic drugs Naproxen (Naproxen) and Isradipine (Isradipine);
- KIT-302: Based on Celecoxib and the generic drug Amlodipine besylate, the Phase III clinical trial has been completed (2015.12.15).
Both naproxen and celecoxib are the active ingredients of drugs that have been approved to relieve arthritis pain, and Celecoxib is the active ingredient of the brand-name drug Celebrex®.
The above drug combination is designed to treat arthritis and hypertension (hypertension is one of the side effects of using Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) to treat arthritis).
On December 15, 2015, Kitov Pharmaceuticals (KTOV) announced that the third phase clinical trial of its product KIT-302 has reached the initial effect target, which is a clinical benchmark and has been approved by the FDA.
Kitov Pharmaceuticals (KTOV) investment:
Company’s official website | Market trend
Kitov Pharmaceuticals Holdings Ltd submitted its IPO prospectus on 9/24/2015 and landed on Nasdaq on 11/20/2015. The issue price is 9.33 US dollars. It plans to raise 50.87 million US dollars. The stock code is KTOV.